Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET

Company Participants

Luis Sanay - Head, IR

Jeffrey Dayno - President & CEO

Jeffrey Dierks - Chief Commercial Officer

Kumar Budur - Chief Medical Officer

Sandip Kapadia - CFO

Conference Call Participants

Francois Brisebois - Oppenheimer

David Amsellem - Piper Sandler

Eason Lee - Needham & Co.

Charles Duncan - Cantor Fitzgerald

Jason Gerberry - Bank of America

Graig Suvannavejh - Mizuho Securities

Corinne Jenkins - Goldman Sachs

Operator

Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Third Quater 2023 Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference call may be recorded. [Operator Instructions]

I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Luis Sanay

Thank you, Operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2023 financial results and provide a business update.

Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.

Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer.

As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.

I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff?

Jeffrey Dayno

Thank you, Luis, and thanks, everyone, for joining our conference call today. Q3 2023 was the strongest revenue quarter in Harmony's history. The pace of growth in net revenue and average number of patients on WAKIX is rarely seen in year four of commercialization of an orphan rare disease product. What is driving this strong continued growth of WAKIX in narcolepsy is the meaningfully differentiated product profile, the strong underlying patient demand, the sizable market of 80,000 patients diagnosed with narcolepsy in the U.S., and the consistent executional excellence of our commercial organization.